SPL 7.14% 10.5¢ starpharma holdings limited

Questions to be answered now....not in seven weeks time, page-12

  1. 5,067 Posts.
    lightbulb Created with Sketch. 562

    this thread suggests questions to SPL not attacks, a please explain in detail why certain things are happening...
    and its not ok to use Covid delays as an excuse and many issue come from a time well before covid...

    why are our products not being sold... some are by far and away worthy of FDA approval and there much need market.
    The status of devices via a high court judgement over in the US was in favour of a pharma against the FDA requiring the FDA to look to its approvals or non approval for the past... surely we would fit into that space.. with VB gel..

    what is has there been a total lack of quality market, promos, TV ads...list goes one... not just a fluffy speil alongside hand care cream or vicks, like in the UK, .
    just for a start...
    There is heaps of coverage in the Australia media of various treatment, medications etc... and without TGA approval at the moment.. yet the media speil is like they are appoved already. ... yet viraleze is it seem ilde after 12 months...
    Could a trial be done on one those container ships full of covid people being isolated off shore..... even a limit trial ot issue free product in a confined cohort.... result should show - a quick response to viral loads... at a minium

    why have timelines been said to occure soon yet years later nothing, promise of contract to be signed and yet nothing out of india, Europe is vague, and the UK is hard to even discribe.

 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.007(7.14%)
Mkt cap ! $43.29M
Open High Low Value Volume
9.5¢ 10.5¢ 9.5¢ $8.154K 83.09K

Buyers (Bids)

No. Vol. Price($)
1 5102 9.8¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 124847 3
View Market Depth
Last trade - 16.10pm 11/07/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.